HPLC-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Radioactive decay results in a reduction of summed rest mass, once the released energy (the disintegration energy) has escaped in some way. Although decay energy is sometimes defined as associated with the difference between the mass of the parent nuclide products and the mass of the decay products, this is true only of rest mass measurements, where some energy has been removed from the product system. This is true because the decay energy must always carry mass with it, wherever it appears (see mass in special relativity) according to the formula E = mc2. The decay energy is initially released as the energy of emitted photons plus the kinetic energy of massive emitted particles (that is, particles that have rest mass). If these particles come to thermal equilibrium with their surroundings and photons are absorbed, then the decay energy is transformed to thermal energy, which retains its mass. Decay energy, therefore, remains associated with a certain measure of the mass of the decay system, called invariant mass, which does not change during the decay, even though the energy of decay is distributed among decay particles. The energy of photons, the kinetic energy of emitted particles, and, later, the thermal energy of the surrounding matter, all contribute to the invariant mass of the system. Thus, while the sum of the rest masses of the particles is not conserved in radioactive decay, the system mass and system invariant mass (and also the system total energy) is conserved throughout any decay process.
Urocortin 2 (Ucn2) is an endogenous peptide in the corticotrophin-releasing factor (CRF) family. Urocortin II is a 38-amino acid peptide that is a member of the CRF family of peptides. Unlike Urocortin I, Urocortin II is highly selective for the CRF2 receptor and does not show affinity for the CRF binding protein.
Another parish church in Bromley is St Mark's, which stands on Westmoreland Road. The present church is the third. The first was built as a temporary iron church in 1884 to cope with Bromley's growing population, on land slightly to the east of the present church, donated by a local man Eley Soames. The road name St Mark's Road preserves the rough location of the former site. The second church was built in brick and stone on the present site, and designed by Evelyn Hellicar, son of the then vicar of St Peter and St Paul's. It was completed in 1898 in the Perpendicular Gothic style and consecrated by William Walsh, Bishop of Dover, on 22 October that year. The tower, though, was not completed until 1904. Like St Peter and St Paul's, St Mark's was heavily damaged in the London Blitz of 1941. Only the tower survived intact. On 3 June 1952, the Duchess of Kent laid the foundation stone of the present church, which was designed by T W G Grant and built by David Nye. Besides the tower, other parts of the fabric of the original church were used in the rebuilding. Inside there are various monuments: to Samuel Ajayi Crowther, John Cole Patteson and Vedanayagam Samuel Azariah, who were all bishops in the Commonwealth. The East Street drill hall was completed in 1872.
Sources: en.wikipedia.org
Orthostatic intolerance (OI) is a disorder of the autonomic nervous system (a subcategory of dysautonomia) characterized by the onset of symptoms upon standing. Symptoms include fatigue, lightheadedness, headache, weakness, increased heart rate/heart palpitations, anxiety, and altered vision. Often, patients have high plasma norepinephrine (NE) concentrations (at least 600 pg/ml) in relation to sympathetic outflow upon standing, suggesting OI is a hyperadrenergic condition. The discovery of identical twin sisters who both had OI suggested a genetic basis for the disorder. A missense mutation on the NET gene (SLC6A2) was discovered in which an alanine residue was replaced with a proline residue (Ala457Pro) in a highly conserved region of the transporter. The patients' defective NET had only 2% of the activity of the wild-type version of the gene. The genetic defect in the NET protein results in decreased NET activity that could account for abnormally high NE plasma levels in OI. However, 40 other OI patients did not have the same missense mutation, indicating other factors contributed to the phenotype in the identical twins. This discovery of the linkage with NET mutations that results in decreased norepinephrine reuptake activity and orthostatic intolerance suggests faulty NE uptake mechanisms can contribute to cardiovascular disease.
== Instrumentation == The CI source design for a mass spectrometer is very similar to that of the EI source. To facilitate the reactions between the ions and molecules, the chamber is kept relatively gas tight at a pressure of about 1 torr. Electrons are produced externally to the source volume (at a lower pressure of 10−4 torr or below) by heating a metal filament which is made of tungsten, rhenium, or iridium. The electrons are introduced through a small aperture in the source wall at energies 200–1000 eV so that they penetrate to at least the centre of the box. In contrast to EI, the magnet and the electron trap are not needed for CI, since the electrons do not travel to the end of the chamber. Many modern sources are dual or combination EI/CI sources and can be switched from EI mode to CI mode and back in seconds.
genetically modified organism (GMO) Any organism whose genetic material has been altered using genetic engineering techniques, particularly in a way that does not occur naturally by mating or by natural genetic recombination.
de Lorenzo, Victor; Schmidt, Markus (April 2016). "Synthetic bugs on the loose: containment options for deeply engineered (micro)organisms". Current Opinion in Biotechnology. 38: 90–96. doi:10.1016/j.copbio.2016.01.006. PMID 26874261.
Sources: en.wikipedia.org
In February 2013, Essendon announced that they had asked the Australian Sports Anti-Doping Authority (ASADA) to investigate the supplements program that Dank had overseen at their club during the 2012 season. A former player, Kyle Reimers, had claimed that the players were asked to sign waivers and were injected with supplements that were "pushing the boundaries". Another former player, Mark McVeigh countered that the injections were only vitamins and all were completely legal and not on any World Anti-Doping Agency (WADA) banned substance list. Dank left Essendon at the end of the 2012 season, and high-performance manager Dean 'The Weapon' Robinson was suspended from the club after the announcement of the investigation. Stephen Dank controversially admitted to a Fairfax journalist that he had been using thymosin beta 4 on Essendon players. When journalist Nick McKenzie pointed out that that drug was prohibited by WADA under its S2 classification, Dank hesitated and then seemed extremely surprised: "Well, that must have just only come in this year and I will get someone to speak to ASADA about that. That's just mind-blowing." After 24 hours, Dank informed Fairfax media that he was actually really talking about thymomodulin which was a permitted substance. In 2015, the AFL Tribunal found him guilty of trafficking in a number of illicit supplements and banned him from any association with the AFL for life. Since most Australian sporting organisations honour sanctions imposed by other leagues, this had the effect of blackballing Dank from major Australian sport.
According to the National Drug Intelligence Center, Mexican cartels are the predominant smugglers and wholesale distributors of South American cocaine and Mexico-produced cannabis, methamphetamine, and heroin. The U.S. State Department estimates that 90 percent of cocaine entering the United States is produced in Colombia, followed by Bolivia and Peru, and that the main transit route is through Mexico. Mexican cartels control large swaths of territory, and most of the illegal drugs coming into the U.S., employing land routes, maritime shipments, smuggling tunnels, and other concealment methods. Cartels have waged violent turf battles over control of key smuggling corridors from Matamoros to Tijuana. Cartels operate clandestine laboratories that process precursor chemicals into synthetic drugs. These chemicals are primarily imported from Asia, especially China and India, and are used to manufacture methamphetamine and fentanyl in large quantities. Since the 2010s, fentanyl has become one of the most profitable components of cartel operations due to its low production cost and high potency. Although Mexico accounts for only a small share of worldwide heroin production, it supplies a large share of the heroin distributed in the United States. Since the 2000s, Mexican cartels have profited from marijuana cultivation in remote U.S. forests. A 2018 study found that the reduction in drugs from Colombia contributed to Mexican drug violence.
=== Separation methods === Initially, analytes in a metabolomic sample comprise a highly complex mixture. This complex mixture can be simplified prior to detection by separating some analytes from others. Separation achieves various goals: analytes which cannot be resolved by the detector may be separated in this step; in MS analysis, ion suppression is reduced; the retention time of the analyte serves as information regarding its identity. This separation step is not mandatory and is often omitted in NMR and "shotgun" based approaches such as shotgun lipidomics. Gas chromatography (GC), especially when interfaced with mass spectrometry (GC-MS), is a widely used separation technique for metabolomic analysis. GC offers very high chromatographic resolution, and can be used in conjunction with a flame ionization detector (GC/FID) or a mass spectrometer (GC-MS). The method is especially useful for identification and quantification of small and volatile molecules. However, a practical limitation of GC is the requirement of chemical derivatization for many biomolecules as only volatile chemicals can be analysed without derivatization. In cases where greater resolving power is required, two-dimensional chromatography (GCxGC) can be applied. High performance liquid chromatography (HPLC) has emerged as the most common separation technique for metabolomic analysis. With the advent of electrospray ionization, HPLC was coupled to MS.
==== Elimination ==== Tizanidine is eliminated 60% in urine and 20% in feces. Its elimination half-life is approximately 2.5 hours. The inactive metabolites of tizanidine have half-lives of 20 to 40 hours.
While lifetime medical costs for obese individuals may be lower than for healthy weight individuals, obese individuals cause significant economic productivity loss (ranging from $13.4 billion to $26.8 billion in 2016). The obesity rate has steadily increased since 1960–1962, where approximately 13% of American adults were obese. By 2014, figures from the CDC found that more than one-third (crude estimate 36.5%) of U.S. adults and 17% of children were obese. By 2014, figures from the National Institute of diabetes shows that 82% of Americans are overweight. National Center for Health Statistics at the CDC showed that 42.4% of U.S. adults were obese as of 2017–2018 (43% for men and 41.9% for women). The National institute of Diabetes states that 73.1% of Americans were obese or overweight as of 2017-2018. For the following statistics, "adult" is defined as age 20 and over. The overweight + obese percentages for the overall US population are higher reaching 39.4% in 1997, 44.5% in 2004, 56.6% in 2007, 63.8% (adults) and 17% (children) in 2008, in 2010 65.7% of American adults and 17% of American children are overweight or obese, and 63% of teenage girls become overweight by age 11. In 2013 the Organization for Economic Co-operation and Development (OECD) found that 57.6% of all American citizens were overweight or obese. The organization estimated that 3/4 of the American population would likely be overweight or obese by 2020. According to research done by the Harvard T.H.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.